Xeris Biopharma director receives equity grants

Xeris Biopharma Holdings, Inc. director Garheng Kong reported receiving new equity awards as part of his compensation.

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. director Garheng Kong reported receiving new equity awards as part of his compensation. He was granted 24,193 shares of common stock in the form of restricted stock units under the company’s 2018 Stock Option and Incentive Plan. Following this award, his direct common stock holdings total 238,337 shares.

He also received a stock option for 32,996 shares of common stock with an exercise price of $6.15 per share, expiring on June 4, 2036. Both the restricted stock units and the stock options vest in full on the earlier of June 4, 2026 or the date of the company’s next annual meeting of stockholders, provided he continues to serve through the vesting date.

Insider Trade Summary

Grant/Award: 57,189 shares

Grant/Award 2 txns

Insider Kong Garheng

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,996	$6.15	$203K
Grant/Award	Common Stock	24,193	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 32,996 contracts (Direct); Common Stock — 238,337 shares (Direct)

Footnotes (2)

1. F1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
2. F2. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Key Figures

RSU grant: 24,193 shares Common shares held: 238,337 shares Stock options granted: 32,996 options +3 more

6 metrics

RSU grant 24,193 shares Restricted stock unit grant to director Garheng Kong

Common shares held 238,337 shares Direct common stock holdings after RSU grant

Stock options granted 32,996 options New stock option award linked to common stock

Option exercise price $6.15 per share Exercise price for 32,996 stock options

Option expiration June 4, 2036 Expiration date for stock option grant

Vesting date trigger June 4, 2026 Awards vest on earlier of this date or next annual meeting

Key Terms

restricted stock unit, 2018 Stock Option and Incentive Plan, stock options, exercise price, +1 more

5 terms

restricted stock unit financial

"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2018 Stock Option and Incentive Plan financial

"acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"

stock options financial

"These stock options were acquired pursuant to a grant under the Plan."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"transaction_price_per_share": "6.1500" and conversion_or_exercise_price": "6.1500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Xeris Biopharma (XERS) report for Garheng Kong?

Xeris Biopharma reported that director Garheng Kong received equity awards as compensation. He was granted restricted stock units and stock options that increase his direct ownership and potential future stake in the company, subject to vesting conditions.

How many Xeris Biopharma (XERS) shares were granted to director Garheng Kong?

Garheng Kong received 24,193 shares of common stock through a restricted stock unit grant. These shares represent a contingent right to receive common stock once vesting conditions are met, aligning his compensation more closely with shareholder interests.

What stock options did Garheng Kong receive from Xeris Biopharma (XERS)?

He was granted stock options covering 32,996 shares of Xeris Biopharma common stock at an exercise price of $6.15 per share. These options give him the right to buy shares at that price if they vest and he chooses to exercise them before expiration.

When do Garheng Kong’s new Xeris Biopharma (XERS) equity awards vest?

Both the restricted stock units and the stock options vest in full on the earlier of June 4, 2026, or the date of Xeris Biopharma’s next annual meeting of stockholders. Vesting requires his continued service through the applicable date.

What is Garheng Kong’s Xeris Biopharma (XERS) share ownership after this Form 4?

After the restricted stock unit grant, Garheng Kong directly holds 238,337 shares of Xeris Biopharma common stock. This figure reflects his reported direct ownership position following the latest equity award disclosed in the Form 4 filing.

Under which plan were Garheng Kong’s Xeris Biopharma (XERS) awards granted?

The restricted stock units and stock options were granted under Xeris Biopharma’s 2018 Stock Option and Incentive Plan. This plan is used to provide equity-based compensation to directors and other participants to support long-term alignment with shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 06:39 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kong Garheng

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		24,193(1)	A	$0	238,337	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.15	06/04/2026		A		32,996		(2)	06/04/2036	Common Stock	32,996	$6.15	32,996	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

2. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Remarks:

	/s/ Beth Hecht, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)